Publication:
Blood group-specific apheresis in combination with daratumumab as a rescue therapy of acute antibody-mediated rejection in a case of ABO- and human leukocyte antigen-incompatible kidney transplantation

Simple item page
dc.contributor.coauthorKraft, Leonie
dc.contributor.coauthorEnder, Andrea
dc.contributor.coauthorSuesal, Caner
dc.contributor.coauthorSchwenger, Amelie
dc.contributor.coauthorAmann, Kerstin
dc.contributor.coauthorBoehmig, Georg A.
dc.contributor.coauthorSchwenger, Vedat
dc.contributor.kuauthorSüsal, Caner
dc.contributor.researchcenterKoç University Transplant Immunology Research Centre of Excellence (TIREX)
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.unitKoç University Hospital
dc.date.accessioned2024-12-29T09:40:45Z
dc.date.issued2023
dc.description.abstractWe report a case of antibody-mediated rejection treated with the human CD38 monoclonal antibody daratumumab in a 58-year-old female patient with end-stage kidney disease due to autosomal dominant polycystic kidney disease who received an ABO- and human leukocyte antigen antibody-incompatible living donor kidney transplant. The patient experienced an episode of severe antibody-mediated rejection within the first week of transplantation. Blood-group-antibody selective immunoadsorption in combination with administration of four doses of daratumumab (each 1800 mg s.c.) led to a persistent decrease of ABO- and more interestingly donor-specific human leukocyte antigen antibody reactivity and resulted in clinical and histopathological remission with full recovery of graft function, which has remained stable until post-transplant day 212. This case illustrates the potential of targeting CD38 in antibody-mediated rejection.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessgold, Green Published
dc.description.publisherscopeInternational
dc.description.sponsorsAll authors approved the final version of the manuscript.
dc.description.volume11
dc.identifier.doi10.1177/2050313X231211050
dc.identifier.issn2050-313X
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-85176450853
dc.identifier.urihttps://doi.org/10.1177/2050313X231211050
dc.identifier.urihttps://hdl.handle.net/20.500.14288/23423
dc.identifier.wos1096667000001
dc.keywordsCase report
dc.keywordsDaratumumab
dc.keywordsAntibody-mediated rejection
dc.keywordsKidney transplantation
dc.keywordsLiving-donor transplantation
dc.keywordsHLA incompatibility
dc.keywordsBlood-group incompatibility
dc.keywordsRejection therapy
dc.languageen
dc.publisherSage Publications Inc
dc.relation.grantnoAll authors approved the final version of the manuscript.
dc.sourceSage Open Medical Case Reports
dc.subjectMedicine
dc.subjectGeneral
dc.subjectInternal
dc.titleBlood group-specific apheresis in combination with daratumumab as a rescue therapy of acute antibody-mediated rejection in a case of ABO- and human leukocyte antigen-incompatible kidney transplantation
dc.typeJournal article
dspace.entity.typePublication
local.contributor.kuauthorSüsal, Caner

Files

Collections

Publications without Fulltext